Crossovers pile into $110M series B as Vor heads into the clinic

Vor's $110 million series B round gives the hematopoietic stem cell play enough fuel to keep its financing options open as it advances its lead program into the clinic.

RA Capital led the round, which saw participation from new investors Fidelity Management & Research Co., Pagliuca Family Office, Alexandria Venture Investments and additional undisclosed investors including crossover investors, as well as fellow existing investors 5AM Ventures, Johnson & Johnson Innovation - JJDC Inc., Osage University Partners and PureTech Health plc (LSE:PRTC)...